

# Jason Madore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4071024/publications.pdf>

Version: 2024-02-01

42  
papers

6,472  
citations

136885

32  
h-index

289141

40  
g-index

43  
all docs

43  
docs citations

43  
times ranked

12101  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. <i>New England Journal of Medicine</i> , 2010, 363, 1532-1543.	13.9	1,460
2	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	13.9	706
3	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	7.7	547
4	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1 clinical trials. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 245-253.	1.5	356
5	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , 2013, 14, 853-862.	5.1	335
6	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	3.2	297
7	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.4	270
8	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <i>Lung Cancer</i> , 2015, 89, 181-188.	0.9	253
9	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	3.2	192
10	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. <i>Histopathology</i> , 2016, 69, 25-34.	1.6	177
11	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. <i>Cancer Discovery</i> , 2019, 9, 1754-1773.	7.7	173
12	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.4	126
13	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1421-1433.	0.5	121
14	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. <i>Journal of Pathology</i> , 2010, 220, 392-400.	2.1	92
15	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3915-3923.	3.2	91
16	Recurrent inactivating RASA2 mutations in melanoma. <i>Nature Genetics</i> , 2015, 47, 1408-1410.	9.4	90
17	Tumor intrinsic and extrinsic immune functions of CD155. <i>Seminars in Cancer Biology</i> , 2020, 65, 189-196.	4.3	85
18	BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis. <i>PLoS ONE</i> , 2012, 7, e38541.	1.1	84

#	ARTICLE	IF	CITATIONS
19	Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. <i>Oncotarget</i> , 2015, 6, 27023-27036.	0.8	83
20	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
21	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019, 7, 559-571.	1.6	79
22	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	6.6	79
23	H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ER $\alpha$ ligand dependency. <i>EMBO Journal</i> , 2011, 30, 3947-3961.	3.5	77
24	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. <i>Oncotarget</i> , 2015, 6, 21507-21521.	0.8	72
25	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. <i>Oncolmmunology</i> , 2019, 8, e1581530.	2.1	69
26	Role of Pirh2 in Mediating the Regulation of p53 and c-Myc. <i>PLoS Genetics</i> , 2011, 7, e1002360.	1.5	65
27	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncolmmunology</i> , 2019, 8, e1537581.	2.1	61
28	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. <i>Pathology</i> , 2016, 48, 574-580.	0.3	59
29	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
30	From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2006, 118, 1750-1758.	2.3	49
31	HDAC inhibitors restore BRAF $\alpha$ inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. <i>International Journal of Cancer</i> , 2018, 142, 1926-1937.	2.3	48
32	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. <i>Biopreservation and Biobanking</i> , 2013, 11, 83-93.	0.5	35
33	Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 171-179.	1.6	24
34	An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer. <i>Cancer</i> , 2007, 110, 297-308.	2.0	18
35	A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. <i>Journal of Investigative Dermatology</i> , 2019, 139, 467-469.	0.3	17
36	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828.	1.6	16

#	ARTICLE	IF	CITATIONS
37	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2015, 22, 2972-2977.	0.7	13
38	RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. Scientific Reports, 2018, 8, 653.	1.6	13
39	A novel method of cell embedding for tissue microarrays. Histopathology, 2010, 57, 323-329.	1.6	6
40	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (&lt;Â0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2017, 24, 660-660.	0.7	1
41	The critical role of tumour-resident cytotoxic T cells in human malignancies. Pathology, 2018, 50, S47.	0.3	0
42	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.. Journal of Clinical Oncology, 2018, 36, 9518-9518.	0.8	0